Drug Monographs: Olaratumab and Rucaparib.
作者： Dominic A. Solimando , J. Aubrey Waddell
DOI: 10.1310/HPJ5203-258
关键词: Medical physics 、 Medicine 、 Rucaparib 、 Pharmacology 、 Olaratumab 、 Drug
摘要:
sagepub.com 
hospital-pharmacy.com 参考文章(16)
Arne Östman, Carl-Henrik Heldin, Involvement of platelet-derived growth factor in disease: development of specific antagonists Advances in Cancer Research. ,vol. 80, pp. 1- 38 ,(2001) , 10.1016/S0065-230X(01)80010-5
Carole Beck, Isabelle Robert, Bernardo Reina-San-Martin, Valérie Schreiber, Françoise Dantzer, Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3 Experimental Cell Research. ,vol. 329, pp. 18- 25 ,(2014) , 10.1016/J.YEXCR.2014.07.003
Thomas Helleday, The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings Molecular Oncology. ,vol. 5, pp. 387- 393 ,(2011) , 10.1016/J.MOLONC.2011.07.001
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell, Adrian Harris, Patrick Johnson, Heidi Steinfeldt, Raz Dewji, Diane Wang, Lesley Robson, Hilary Calvert, Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors Clinical Cancer Research. ,vol. 14, pp. 7917- 7923 ,(2008) , 10.1158/1078-0432.CCR-08-1223
Toshihiko Doi, Yan Ma, Aruna Dontabhaktuni, Cornelia Nippgen, Johannes Nippgen, Atsushi Ohtsu, Phase I study of olaratumab in Japanese patients with advanced solid tumors Cancer Science. ,vol. 105, pp. 862- 869 ,(2014) , 10.1111/CAS.12444
Olga Loseva, Ann-Sofie Jemth, Helen E. Bryant, Herwig Schüler, Lari Lehtiö, Tobias Karlberg, Thomas Helleday, PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. Journal of Biological Chemistry. ,vol. 285, pp. 8054- 8060 ,(2010) , 10.1074/JBC.M109.077834
Ruth Plummer, Paul Lorigan, Neil Steven, Lucy Scott, Mark R. Middleton, Richard H. Wilson, Evan Mulligan, Nicola Curtin, Diane Wang, Raz Dewji, Antonello Abbattista, Jorge Gallo, Hilary Calvert, A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation Cancer Chemotherapy and Pharmacology. ,vol. 71, pp. 1191- 1199 ,(2013) , 10.1007/S00280-013-2113-1
Amy Qin, Aruna Dontabhaktuni, Nick Loizos, Johannes Nippgen, Robert Amato, E. Gabriela Chiorean, Christopher Sweeney, Hagop Youssoufian, A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology. ,vol. 73, pp. 595- 604 ,(2014) , 10.1007/S00280-014-2389-9
Michèle Rouleau, Anand Patel, Michael J. Hendzel, Scott H. Kaufmann, Guy G. Poirier, PARP inhibition: PARP1 and beyond Nature Reviews Cancer. ,vol. 10, pp. 293- 301 ,(2010) , 10.1038/NRC2812
Junko Murai, Shar-yin N. Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H. Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier, Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors Cancer Research. ,vol. 72, pp. 5588- 5599 ,(2012) , 10.1158/0008-5472.CAN-12-2753